ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
Read More
ViiV Healthcare has initiated a Phase III study exploring the efficacy of long-acting cabotegravir for the prevention of HIV infection in sexually active women.
Read More
NHS England has kicked off what it claims to be the world’s largest single trial assessing the full impact of a scheme that gives patients at high risk of contracting HIV drugs to prevent infection.
Read More
Scotland will become the first UK nation to routinely offer HIV pre-exposure prophylaxis to all eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada alongside four other new therapies to be funded by the NHS.
Read More
NHS England has announced that it will fund a “major extension” of Public Health England’s HIV prevention programme to help reduce the incidence of the disease across the country.
Read More
The Court of Appeal has ruled that NHS England does indeed have the legal power to fund what campaigners refer to as a “game-changing” drug to prevent the transmission of HIV under a strategy called Pre-Exposure Prophylaxis (PrEP).
Read More
The National Institute for Health and Care Excellence has published an evidence summary on the use of Gilead’s Truvada for HIV pre-exposure prophylaxis (PrEP) in adults at high risk of infection.
Read More
European regulators have issued a green light for the use of Gilead’s Truvada to cut the risk of HIV infection in adults.
Read More
